MATTHEW C. REYNEN, M.D.

ABERDEEN, SD

Research Active
Orthopaedic Surgery NPI registered 21+ years 3 publications 1988 – 1991 NPI: 1245236785
RatsRats, Inbred StrainsGene Expression Regulation, BacterialGenetic VectorsPromoter Regions, GeneticMolecular Sequence DataBase SequenceSubstance Withdrawal SyndromeDrug SynergismGram-Negative BacteriaCalcium ChannelsCloning, MolecularDiltiazemPyruvate DecarboxylasePentobarbital

Practice Location

701 8TH AVENUE NW SUITE A
ABERDEEN, SD 57401

Phone: (605) 226-2663

What does MATTHEW REYNEN research?

Dr. Reynen studies how drugs affect withdrawal symptoms, specifically in animal models like rats. He has investigated how the drug diltiazem influences the discomfort experienced by rats dependent on another drug called pentobarbital. On the biotechnology side, he works with the bacterium Zymomonas mobilis, which is important in biofuel production. He has developed genetic tools that enhance the ability to express genes in this bacterium, making it more effective for various applications, including renewable energy sources.

Key findings

  • Rats treated with diltiazem lost about 10% of their body weight during withdrawal, compared to 5% in the placebo group.
  • Both treated and untreated groups showed a significant drop in water intake and increased withdrawal scores, indicating similar discomfort levels.
  • One expression vector developed can produce enzyme activity levels as high as 5.5 units per milligram of protein.

Frequently asked questions

Does Dr. Reynen study drug withdrawal?
Yes, he investigates how medications like diltiazem affect withdrawal symptoms in drug-dependent models.
What treatments has Dr. Reynen researched?
He studied the effects of diltiazem on withdrawal symptoms in rats.
Is Dr. Reynen's work relevant to biofuel production?
Yes, he develops genetic tools for the bacterium Zymomonas mobilis, which is used in biofuel applications.
What is Zymomonas mobilis?
It is a type of bacterium that can be engineered to produce biofuels and other products.
How does Dr. Reynen's work help scientists?
His research provides new tools for genetic engineering and insights into managing drug withdrawal.

Publications in plain English

Diltiazem alters some withdrawal signs in pentobarbital-dependent rats.

1991

Pharmacology, biochemistry, and behavior

Yutrzenka GJ, Reynen M

Plain English
The research studied how the drug diltiazem affects withdrawal symptoms in rats that had become dependent on a drug called pentobarbital. The findings showed that while rats treated with diltiazem lost about 10% of their body weight during withdrawal, those given a placebo only lost about 5%. Additionally, both groups of rats had a significant drop in water intake and increased withdrawal scores, indicating similar levels of discomfort, showing that diltiazem did not improve withdrawal symptoms. Who this helps: This research is relevant for scientists and healthcare providers looking for ways to manage drug withdrawal in patients.

PubMed

Construction of expression vectors for the gram-negative bacterium Zymomonas mobilis.

1990

Molecular & general genetics : MGG

Reynen M, Reipen I, Sahm H, Sprenger GA

Plain English
This study created new tools, called expression vectors, that allow scientists to introduce and work with specific genes in the bacterium Zymomonas mobilis. The researchers developed three different vectors (pPTZ1, pPTZ3, and pPTZ4) that help control how genes are expressed, and they found that one of these vectors could produce enzyme activity levels as high as 5.5 units per milligram of protein. This is important because it improves scientists' ability to use Z. mobilis for various applications, including biofuel production. Who this helps: This benefits researchers and companies working on biofuels and biotechnology.

PubMed

Comparison of the structural genes for pyruvate decarboxylase in different Zymomonas mobilis strains.

1988

Journal of bacteriology

Reynen M, Sahm H

Plain English
This study looked at the gene responsible for making an enzyme called pyruvate decarboxylase in two different strains of the bacteria Zymomonas mobilis. The researchers found that the gene from one strain (ATCC 29191) is different from the gene in another strain (ATCC 31821). These differences can affect how the enzyme works, which is important for using these bacteria in making biofuels and other products. Who this helps: This benefits researchers and companies working on biofuels and fermentation technologies.

PubMed

Frequent Co-Authors

H Sahm G J Yutrzenka I Reipen G A Sprenger

Physician data sourced from the NPPES NPI Registry . Publication data from PubMed . Plain-English summaries generated by AI. Not medical advice.